Who are the leading innovators in neoepitope prediction for the pharmaceutical industry?

According to GlobalData’s Technology Foresights, which uses over 668,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry.

Neoepitope prediction is a key innovation area in immuno-oncology

Neoepitope prediction involves the identification and prediction of neoepitopes. Neoepitopes are short peptide sequences derived from proteins that are not present in the normal or healthy cells of an organism but are generated due to mutations, aberrant splicing, or other alterations in the cancerous or diseased cells. These are unique to an individual’s cancer cells, which can then be targeted with personalized immunotherapies.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 150+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of neoepitope prediction.

Key players in neoepitope prediction – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.   

‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.  

Patent volumes related to neoepitope prediction

Codexis is one of the leading patent filers in neoepitope prediction. The protein engineering company discovers, develops, and markets synthetic proteins for a wide range of applications. It sells biocatalysts for the commercial manufacturing of pharmaceuticals, industrial enzymes and fine chemicals, and enzymes as biotherapeutics and for use in molecular diagnostics. The company identifies, optimizes and produces enzymes by using CodeEvolver, its proprietary protein engineering technology platform, which introduces mutation into genes to transform the enzymes that they produce. BioNTech and Johnson & Johnson are some of the other key patent filers in neoepitope prediction.

In terms of application diversity, Orig3N leads the pack, while Immatics and LipoScience stood in the second and third positions, respectively. By means of geographic reach, BioNTech held the top position, followed by TRON  and Immatics.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Immuno-oncology (IO).

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.